CJC-1295
A synthetic GHRH analogue designed for extended plasma half-life; the DAC (Drug Affinity Complex) form binds albumin to achieve roughly six to eight days of activity per dose. Reportedly investigated for growth hormone stimulation, body composition, and recovery by signalling the pituitary upstream of GH itself. One Phase II pharmacokinetic trial in healthy adults has been published; controlled therapeutic evidence for the applications most frequently discussed in community contexts is limited.
Side effects & risks
CJC-1295 has not been approved for human therapeutic use by any major regulatory authority. No large-scale, long-term safety studies in humans have been published. The risk profile for unsupervised use is, in practical terms, unknown.
The published Phase II trials reported by Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 3; PMID 16352683) stated that no serious adverse reactions were observed in those studies. This does not constitute a comprehensive long-term safety profile; the studies were short-duration ascending-dose trials in healthy adults and do not establish the risk profile for chronic use at community-reported protocols.
As a GHRH analogue, CJC-1295 produces sustained elevation of GH and IGF-1 levels. The long-term consequences of chronic IGF-1 elevation — including theoretical implications for cancer biology and metabolic parameters — have not been evaluated in human safety trials of the durations relevant to community usage patterns.
Community reports of adverse effects from CJC-1295 without DAC (the shorter-acting form) include injection-site reactions, transient water retention, mild headache, and flushing. The DAC-containing form is associated with more sustained GH elevation and thus longer exposure to any GH-mediated effects per dose. Causality and frequency of these reported effects cannot be established.
CJC-1295 is not approved for human therapeutic use in any major regulatory jurisdiction. Individuals obtaining it as a research chemical assume an undetermined risk profile.
Evidence summary
Latest studies
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Researchers systematically searched the published literature on six peptides marketed for injury recovery and athletic performance - BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu - and found that about two-thirds of the studies were preclinical, mostly in rats. The handful of human studies were small, often lacked robust control groups, and showed at best modest changes in metabolic bone health measures and degenerative knee pain. The authors also flag documented risks, including congestive heart failure with MK-677 and insulin resistance, and conclude the marketing claims are not yet substantiated by human trials.
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
This review discussed the growing use of peptides and peptide-like drugs to enhance muscle, fat loss and recovery in sport and bodybuilding. It is an expert commentary summarising the field, not a new experiment. The authors explained that these peptides, including growth-hormone-releasing peptides such as ipamorelin, growth-hormone-releasing hormone analogues such as CJC-1295 and sermorelin, and fragments such as Frag 176-191 and KPV, are promoted as more selective and supposedly safer than anabolic steroids. However, they stressed that the clinical evidence is limited, because most studies tested careful medical doses, not the very high or combined doses often used in bodybuilding. They pointed to emerging risks including strain on the heart, insulin resistance, abnormal blood fats, and mood and psychiatric instability, and warned that a largely unregulated supply means products are often mislabelled or contaminated. They also noted that how widely these peptides are used, especially among ordinary gym-goers and younger people, is simply unknown. The authors concluded that peptides remain experimental substances with poorly understood long-term risks, and that until long-term studies exist, their use in competitive and recreational settings should be regarded as high-risk and ethically problematic.
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
This review pulled together human and lab-based research from 2020 to 2025 on injectable peptides marketed for muscle, joint and tissue recovery in sports medicine. It is a structured summary of existing studies, not new research, and the authors rated the underlying evidence as generally weak. They sorted the peptides into five groups. Only GLP-1 receptor agonists such as semaglutide had repeatable randomised-trial evidence of easing symptoms, specifically in knee osteoarthritis, and that benefit seemed to come mainly from weight loss and possible anti-inflammation rather than from rebuilding cartilage, which was not shown. Collagen-based injections showed early, limited signs of helping recovery after surgery in small single-centre studies. The so-called regenerative peptides (such as BPC-157 and thymosin derivatives) and growth-hormone-boosting peptides (such as CJC-1295, ipamorelin and tesamorelin) were described as still experimental, with unclear safety, concerns about product quality and contamination, and widespread bans in competitive sport. The authors concluded that most injectable peptides for sports use remain experimental, that use should be limited to approved medicines for approved conditions or to proper research, and that athletes should be counselled about uncertain benefit, quality and anti-doping risks.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“CJC-1295 DAC vs no DAC (Mod GRF 1-29): the single structural difference and what the papers show”
A community explainer contrasting CJC-1295 DAC with the no-DAC form (Mod GRF 1-29), focusing on the one structural modification that separates them and summarizing what the published research says about half-life and GH-release patterns.
“CJC-1295 no DAC”
A biohacking-community thread asking about CJC-1295 without DAC, likely covering dosing, timing, and how the shorter-acting form is used in reported GH-secretagogue protocols.
“CJC-1295 + Ipamorelin”
A discussion of the widely used CJC-1295 plus Ipamorelin combination, the classic GHRH-analog-plus-GHRP pairing, likely covering reported dosing schedules and expected effects.
“CJC-1295 + Ipamorelin for bulking or cutting?”
A user asks whether the CJC-1295 plus Ipamorelin stack is better suited to a bulking or a cutting phase, inviting community input on how GH-secretagogue effects fit different body-composition goals.
“"CJC-1295 + Ipa no DAC" VS "Tesamorelin + Ipa"”
A comparison thread weighing CJC-1295 (no DAC) plus Ipamorelin against Tesamorelin plus Ipamorelin, asking which GHRH-analog pairing the community regards as more effective for their goals.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| GH axis stimulation — DAC form (community-reported) | SC injection | 1–2 mg | 1–2× weekly | 8–12 weeks |
| GH axis stimulation — without DAC (community-reported) | SC injection | 100–300 mcg | 2–3× daily | 8–12 weeks |
Frequently asked questions
- What are the known risks of CJC-1295?
- No large-scale, long-term human safety data has been published. The published Phase II studies (Teichman et al., 2006; PMID 16352683) reported no serious adverse reactions in those short-duration ascending-dose trials; these results do not establish a safety profile for chronic use. The long-term effects of sustained IGF-1 elevation are unstudied at the durations discussed in community use. Community reports include injection-site reactions, water retention, headache, and flushing. The risk profile for extended community use is, in practical terms, unknown.
- What is the difference between CJC-1295 with DAC and without DAC?
- The DAC (Drug Affinity Complex) modification causes CJC-1295 to bind to albumin in the bloodstream, extending its half-life from approximately 30 minutes to an estimated 6 to 8 days (5.8–8.1 days as measured in the Teichman et al. 2006 Phase II trial; PMID 16352683). This produces sustained, prolonged GH and IGF-1 elevation. CJC-1295 without DAC (Mod GRF 1-29) has a shorter half-life and produces a more pulsatile GH release more closely resembling physiological patterns. They act via the same receptor but have very different pharmacokinetic profiles, and should be evaluated separately.
- How strong is the evidence for CJC-1295?
- CJC-1295 has one of the stronger evidence bases among non-approved research peptides, including published Phase II randomised, double-blind, placebo-controlled studies in healthy adults (Teichman et al., 2006; PMID 16352683). These studies confirmed pharmacological activity — significant GH and IGF-1 elevation — and reported no serious adverse reactions. However, they did not demonstrate clinical benefit for any endpoint, and body composition or performance outcomes have not been studied in controlled trials. The evidence for mechanism is strong; evidence for clinical outcomes is insufficient.
- Is CJC-1295 often used with ipamorelin?
- Community members frequently report combining CJC-1295 (without DAC) with ipamorelin, reasoning that the two peptides act via different but complementary pathways — CJC-1295 via the GHRH receptor and ipamorelin via the ghrelin receptor. This combination has not been evaluated in controlled human clinical trials for any outcome. The mechanistic rationale is plausible but the evidence base for the combination is limited to community reports.
- Is CJC-1295 legal to buy or use?
- CJC-1295 is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or most of the EU. In most jurisdictions it is sold as a research chemical. Regulatory status varies by country and is subject to change; verify current status with a qualified legal or clinical professional.